Form 4: Omada Health CEO Sean Duffy Trades Shares

Omada Health CEO Sean P. Duffy reported a transaction involving the sale of common stock, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Sean P. Duffy, Chief Executive Officer and Director of Omada Health, Inc. (OMDA), reported a transaction on June 16, 2026.
• The transaction involved the disposition of 14,960 shares of common stock at a price of $17.3604 per share.
• This sale was conducted under a Rule 10b5-1 trading plan adopted by Mr. Duffy on March 13, 2026.
• Following this transaction, Mr. Duffy directly beneficially owns 411,861 shares of common stock.
• Additionally, he indirectly beneficially owns 851,659 shares held in family trusts for the benefit of his family members, though he disclaims pecuniary interest beyond his own.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the CEO's sale of shares, even though it was conducted under a pre-established plan. The sale itself, regardless of the plan, can sometimes be interpreted as a bearish signal by the market.

Negatives

• The CEO sold a significant number of shares (14,960), which could be perceived negatively by the market, although it was executed under a pre-planned trading strategy.

Risks

• The sale of shares by a key executive could be interpreted as a lack of confidence in the company's future performance, potentially impacting investor sentiment.
• While executed under a 10b5-1 plan, the disposal of shares by the CEO might still raise questions about insider selling.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports a transaction by an executive.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The execution of this sale under a 10b5-1 plan is a common practice for executives to diversify holdings or manage personal finances while adhering to insider trading regulations. The price of $17.3604 per share provides a data point for current valuation discussions.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the CEO's sale with caution, potentially impacting short-term stock sentiment, despite the 10b5-1 plan. However, the continued indirect beneficial ownership through trusts may offer some reassurance.
• Employees: May interpret the CEO's stock sale as a signal about the company's valuation or future prospects, potentially affecting morale.
• Management: The transaction highlights the importance of transparent insider trading policies and compliance.

Key Dates

Keywords

Omada Health, OMDA, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, CEO, Sean P. Duffy, Beneficial Ownership, Securities Exchange Act